Page 692 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

650 PRINCIPES ACTE INTERFÉRANTAVEC LA TUBULINE (POISONS DUFUSEAU

KUEHNE M.E. et al., Enantioselective syntheses of vinblastine, leurosidine vincovaline
and 20'-epi-vincovaline, J. Org. Chem., 1991, 56, 513-528.
MUHTADI F.J. et al., Vinblastine sulfate, in Analytical Profiles of drugs substances and
excipients, Florey K. (Coord.), Academic Press, 1992, vol. 21, 612-658.
LEVEQUE D., JEHL F., Clinicat pharmacokinetics of vinorelbine, Clin. Pharmacol., 1993,
31 (3), 184-97.
VAN TELLINGEN O. et al., Tissue deposition, excretion and metabolism of vinblastine in
mice as determined by high performance liquid chromatography, Cancer Chemother.
Pharmacol., 1993, 32 (4), 286-92.
HARTKE K. et al., Arzneibuch Kommentar. Kommentar zum Europàischen Arzneibuch,
Wissenschaftliche Verlagsgesellschaft, Stuttgart. 5.Lfg. 1995, Vinblastinsulfat V19,
Vincristinsulfat V 20, Vindesinsulfat V21.
TISHLER R.B. et al., Microtubule-active drugs taxol, vinblastine and nocodazole increase
the levels of transcriptionally active p53, Cancer Res., 1995, 55, 6021-25.
ROMINSKY E.K. et al., The effect of food and divided dosing on the bioavailability of oral
vinorelbine, Cancer Chemother. Pharmacol., 1996, 39, 9-16.
RAI S., WOLFF J., Vinblastine-induced formation of tubulin polymers is electrostatically
regulated and nucleated, Eur. J. Biochem., 1997, 250 (2), 425-31.
RIBET J.P. et al., Analyse structurale de la vinorelbine en solution déterminée par spec-
trométrie RMN, Ann. Pharm. Fr., 1997, 55, 20-34.
VERTESSY B.G. et al., Characterization of microtubule-phosphofructokinase complex :
specific effects of MgATP and vinblastine, Biochemistry, 1997, 36 (8), 2051-62.
ETIEVANT C. et al., Vinflunine, a nove! Vinca alkaloid, which participate in P-glycopro-
tein-mediated multidrugresistance in vivo and in vitro, lnvest New Drugs, 1998, 16 (1),
3-17.
PARISH C.A. et al., Circular dichroism studies of bisindole Vinca alkaloids, Tetrahedron,
1998, 54 (52), 15739-58.
BENGTSON E. et al., New oral chemotherapeutic agents for lung cancer, Drugs, 1999,
58 suppl. 3, 57-69.
DOLLERY C., Therapeutic Drugs, 2° ed., Churchill Livingstone, 1999. Vinblastine (sul-
fate), p. V 34-37. Vincristine (sulfate), p. V 37-41.
KARMINSKY N. et al., Vinorelbine-related accute cardiopulmonary toxicity, Cancer Che-
mother. Pharmacol., 1999, 43, 180-182.
GIDDING C.E.M. et al., Vincristine pharmacokinetics after repetitive dosing in children,
CancerChemother Pharmacol., 1999, 44, 203-209.
.
VERDIER-PINARD et al., Differential in vitro association of vinca alkaloid-induced tubulin
spiral filaments into aggregated spirals, Biochem. Pharmacol., 1999, 58 (6), 959-71.
WANG et al., The effect of antimicrotubule agents on signal transduction pathways of
apoptosis: a review, Cancer Chemother. Pharmacol., 1999, 44 (5), 355-61.
BARRET J.M. et al., In vitro synergistic effects of vinflunine in combination with other
anticancer drugs, Cancer Chemother. Pharmacol., 2000, 45, 471-476.
BAU R., KAI JIN K., Crystal structure of vinblastine, J. Chem. Soc., Perkin Trans., 2000,
1, 2079-2082.